Building a peptide approach to sleep — the integrated framework

This is the starting place for thinking about a peptide approach to sleep — not as an alternative to the foundational work, but as the next question to ask once that work is genuinely done.

The first thing to establish, because it matters for everything that follows: if the foundational work hasn't been done, start there. The behavioral side of sleep — what's called cognitive behavioral therapy for insomnia, or CBT-I — is the most evidence-supported treatment for chronic insomnia that exists. It outperforms sleep medication in head-to-head comparisons and produces more durable results. It involves sleep restriction (counter-intuitive and effective), stimulus control (training the brain to associate bed with sleep rather than wakefulness), cognitive restructuring of sleep anxiety, and sleep hygiene as a foundation rather than a complete solution. If you haven't done CBT-I or something like it, that comes before any pharmacological or peptide approach. This isn't a formality. The research on it is unambiguous.

Assuming that foundation is real, the next question is specific: which dimension of sleep is actually broken? Because sleep isn't one thing, and neither are the interventions that target it. Sleep onset — the trouble falling asleep in the first place — is a different problem than sleep maintenance, which is a different problem than sleep depth. Poor sleep depth that doesn't feel like waking may be the hardest problem to self-diagnose because the hours are there and the trouble is invisible. Getting that specific before building any approach is what separates a useful framework from a stack of compounds that may or may not be addressing what's actually wrong.

Sleep onset — trouble falling asleep, racing mind, lying awake for more than twenty to thirty minutes — has specific conventional approaches that work well. Suvorexant and lemborexant are orexin receptor antagonists, FDA-approved for insomnia, and they work by blocking orexin — the wakefulness-promoting neuropeptide — rather than by sedating the brain globally. This mechanism produces sleep that looks more architecturally normal than what you get from traditional sedatives. Trazodone, an antidepressant at higher doses and a common off-label sleep aid at lower doses, works through a different mechanism — H1 histamine blockade and serotonin modulation — and is widely used by prescribing providers for sleep maintenance as well as onset. Low-dose melatonin, timed appropriately (one to two hours before intended sleep time, not immediately before), is the most evidence-supported supplement for sleep timing rather than sleep depth, and works best in people whose circadian timing is misaligned rather than in people whose sleep architecture is simply degraded.

The traditional Z-drugs — zolpidem, eszopiclone — remain widely prescribed and are effective for sleep onset, but carry concerns in chronic use: next-day cognitive impairment, dependence risk, and suppression of slow-wave sleep architecture in some users. They're not necessarily wrong for short-term or situational use; for someone trying to rebuild sleep architecture over months, they're a complicated tool.

This is where the GH-axis peptides become relevant, and the mechanism behind why matters. Slow-wave sleep and growth hormone are coupled. GHRH — growth hormone-releasing hormone — has direct somnogenic properties; it promotes slow-wave sleep through its own receptor activity in the brain, independent of what GH does downstream. When GHRH signaling declines with age, slow-wave sleep declines with it. The GH pulse that depends on slow-wave sleep declines further. The two systems are locked in a feedback relationship that can degrade together over years without a dramatic single event that explains it. Sermorelin, a GHRH analog, may support this signaling and with it the slow-wave architecture that depends on it. Ipamorelin, a selective growth hormone secretagogue, stimulates GH release through a different receptor but produces similar downstream effects on sleep depth in the research. These compounds are researched for their potential to support the hormonal context that deep sleep depends on — not as sleep onset agents, but as architecture-support agents.

MK-677, sometimes discussed alongside these, is a growth hormone secretagogue that's taken orally rather than by injection and has been studied for its effects on GH and IGF-1. It's not technically a peptide in the same category as Sermorelin or Ipamorelin, and it comes with trade-offs that are worth understanding explicitly: it can increase appetite meaningfully, raise fasting glucose in some users, and produce water retention. For some people in specific contexts it's useful; it's not a first choice for sleep architecture support when injectable GH-axis peptides are available. The convenience of oral administration is real, but so are the trade-offs.

DSIP — delta-sleep-inducing peptide — is a compound with a name that states its proposed mechanism directly. It was originally isolated from rabbit brains in the 1970s in the context of research on slow-wave sleep induction. The mechanism involves HPA axis modulation — specifically dampening the cortisol-driven arousal that interferes with sleep depth and maintenance. If your sleep problem is the cortisol-mediated type — the early morning cortisol rise that pulls you into waking at three or four a.m., or the elevated evening cortisol that makes it hard to settle — DSIP's mechanism is pointed at the right thing. The evidence base for DSIP is primarily preclinical and older; the human data is limited. It's researched for its potential role in HPA axis regulation and sleep quality, and it's available through compounding channels. It's not a first-line approach, but for someone whose sleep disruption has a clear cortisol and stress-axis component, it occupies a coherent place in the framework.

Selank, researched for its anxiolytic and neuropeptide Y-modulating effects, addresses a specific presentation: the person who is tired but wired. The one whose body wants to sleep and whose mind won't cooperate — the low-level anxiety that's not quite diagnosable insomnia but keeps the nervous system activated past the arousal threshold that deep sleep requires. Selank has been studied for its potential to support GABA-system activity and reduce sympathetic nervous system tone without the sedation or dependence of benzodiazepines. It's not a sleep compound in the traditional sense; it's an anxiety-modulation compound that may address the upstream activation preventing sleep from reaching its depth. The research is primarily from Russian sources and awaits broader replication, but the mechanism is coherent and the profile — calm without sedation, anxiolysis without blunting — is relevant for the specific sleep-disrupting presentation it addresses.

How does this fit together practically? The framework that makes clinical sense is sequential rather than additive from the start. You identify the specific sleep dimension affected. Sleep onset suggests different interventions than sleep maintenance, which suggests different interventions than sleep depth without obvious waking. You address the foundational behavioral and environmental picture first — not because it will necessarily fix everything, but because without it you can't interpret what any additional intervention is doing. Then you consider single-agent approaches before stacking, because the effect of any individual compound is harder to evaluate when multiple new variables are introduced simultaneously.

For the person whose primary complaint is degraded sleep depth — less restoration, less recovery, blunted GH pulse, the waking-tired-after-sufficient-hours pattern — a GH-axis approach through a prescribing provider is the most mechanistically aligned starting point. Sermorelin or Ipamorelin, dosed at night to coincide with the natural GH pulse, may support the slow-wave architecture that determines sleep quality at a level the behavioral interventions can't reach once the underlying hormonal context has genuinely shifted with age. These are not FDA-approved for sleep; they're researched for their role in GH physiology and are prescribed off-label through providers working in this space.

For the person whose disruption is primarily stress-axis and cortisol-mediated — early morning waking, night-owl wired feeling, a nervous system that treats sleep as optional — the work is upstream of any sleep compound. Autonomic rebalancing through training, stress management, and potentially Selank for the acute anxiety component is the more relevant framework. The hormonal context that sleep occurs in matters more than the compounds you take at bedtime if that context is the primary disrupting factor.

The sleep medicine evaluation worth pursuing, if sleep has been significantly disrupted for months or longer: polysomnography rules out sleep apnea, which is far more common than most people suspect and directly disrupts slow-wave architecture in ways that no peptide will fix. Ruling out apnea before building a peptide protocol for sleep depth is basic clinical sequencing.

What this framework doesn't do is tell you which compound to take. That depends on your specific sleep problem, your clinical picture, your hormonal baseline, your stress load, and your other medications. What it does do is clarify that sleep is a system with specific dimensions, that different interventions target different dimensions, and that peptide approaches to sleep are most useful when they're matched to the specific mechanism that's actually disrupted — not as a general stack applied broadly to a general complaint.

The sleep you're capable of, with the right foundation and the right targeted support, is probably different from what you're getting now. Getting there is a matter of asking the right specific question, not finding the right general answer.